Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How can we symptomatically manage dizziness or risk of fall in older patients on enzalutamide ?
Related Questions
When do you start ADT for a patient with a new diagnosis of node positive prostate cancer receiving radiation?
What is the optimal approach for high risk prostate cancer patients who have been found to have positive nodes after surgery?
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
For a patient post-prostatectomy with a high PSA (>1); and negative MRI pelvis and negative PSMA PET scan; do you pursue any other imaging?
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
How do you manage drug-drug interactions between oral anticoagulants and the ARSI agents such as apalutamide and enzalutamide?
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
Does a negative staging PSMA PET in a patient with biopsy-proven recurrent prostatic adenocarcinoma change your management?
